Compare PLPC & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLPC | PGEN |
|---|---|---|
| Founded | 1947 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2001 | 2013 |
| Metric | PLPC | PGEN |
|---|---|---|
| Price | $346.86 | $4.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $275.00 | $8.33 |
| AVG Volume (30 Days) | 137.5K | ★ 2.7M |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 0.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.14 | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | $17.19 | $1,115.92 |
| Revenue Next Year | $7.28 | $81.04 |
| P/E Ratio | $162.17 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $134.84 | $1.26 |
| 52 Week High | $371.80 | $5.47 |
| Indicator | PLPC | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 57.12 | 54.42 |
| Support Level | $196.73 | $4.12 |
| Resistance Level | N/A | $4.40 |
| Average True Range (ATR) | 23.32 | 0.20 |
| MACD | -0.57 | 0.01 |
| Stochastic Oscillator | 60.54 | 61.06 |
Preformed Line Products Co is a designer and manufacturer of products and systems for constructing and maintaining overhead and underground networks for energy, telecommunication, cable operators, data communication, and other industries. The Company's primary products support, protect, connect, terminate, and secure cables and wires. The Company provides helical solutions, connectors, fiber optic and copper splice closures, solar framing applications, and electric vehicle charging station foundations. The Company's customers include public and private energy utilities and communication companies, cable operators, contractors and subcontractors, distributors, and value-added resellers. Geographically, the company operates in four regions: PLP-USA, the Americas, EMEA, and Asia-Pacific.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.